A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-042
- Sponsors Merck Sharp & Dohme
- 20 Jul 2017 Planned End Date changed from 1 Feb 2018 to 28 Feb 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 28 Feb 2018.
- 20 Jul 2017 Status changed from active, no longer recruiting to recruiting.